Chimeric Therapeutics Ltd (CHM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chimeric Therapeutics Ltd (CHM) has a cash flow conversion efficiency ratio of 1.268x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-3.84 Million ≈ $-2.72 Million USD) by net assets (AU$-3.03 Million ≈ $-2.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Chimeric Therapeutics Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Chimeric Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Chimeric Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Chimeric Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chimeric Therapeutics Ltd ranked by their cash flow conversion efficiency. Explore CHM cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VOLTAGE METALS CORP.
F:8L10
|
0.064x |
|
ImmuPharma PLC
LSE:IMM
|
-2.979x |
|
GO METALS CORP.
F:47GA
|
-0.165x |
|
Ellwee AB
ST:ELLWEE
|
0.503x |
|
EV Digital Invest AG
F:ENGL
|
N/A |
|
Cannassure Therapeutics Ltd
TA:CSURE
|
N/A |
|
HPI AG
MU:CEW3
|
0.018x |
|
Investor Centre Ltd
AU:ICU
|
0.119x |
Annual Cash Flow Conversion Efficiency for Chimeric Therapeutics Ltd (2020–2025)
The table below shows the annual cash flow conversion efficiency of Chimeric Therapeutics Ltd from 2020 to 2025. View Chimeric Therapeutics Ltd (CHM) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$1.97 Million ≈ $1.40 Million |
AU$-7.28 Million ≈ $-5.15 Million |
-3.685x | -20.75% |
| 2024-06-30 | AU$2.47 Million ≈ $1.75 Million |
AU$-7.54 Million ≈ $-5.33 Million |
-3.052x | -5.87% |
| 2023-06-30 | AU$5.66 Million ≈ $4.01 Million |
AU$-16.32 Million ≈ $-11.54 Million |
-2.882x | -463.33% |
| 2022-06-30 | AU$25.71 Million ≈ $18.19 Million |
AU$-13.15 Million ≈ $-9.31 Million |
-0.512x | -45.42% |
| 2021-06-30 | AU$25.13 Million ≈ $17.78 Million |
AU$-8.84 Million ≈ $-6.26 Million |
-0.352x | -166.12% |
| 2020-06-30 | AU$-63.91K ≈ $-45.22K |
AU$-34.01K ≈ $-24.06K |
0.532x | -- |
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more